Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. EBVALLO (tabelecleucel)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

EBVALLO (tabelecleucel)

Medicine - Posted on Jul 11 2023
Active substance (DCI)
  • tabelecleucel
history (2)
  • Economic analysis
    6/7/23

    EBVALLO (tabelecleucel) - Malignant hematopathy

    Primo-inscription. L'essentiel Avis favorable au remboursement en monothérapie dans le traitement des patients adultes et pé...
    CAV :
    54321
    icône flèche
  • 6/1/23

    EBVALLO (tabelecleucel) - Hémopathie maligne

    Autorisation d’accès précoce octroyée à la spécialité EBVALLO (tabelecleucel) dans l’indication « en monothérapie dans le tr...
    icône flèche
Technical information
ATC code
  • L01XL09
Manufacturer
PIERRE FABRE MÉDICAMENT
Presentation

EBVALLO 2,8 × 10^7 - 7,3 × 10^7 cellules/mL, dispersion injectable
1 à 6 flacons copolymère de cyclooléfines (COC) de 1 mL (CIP : 34009 550 946 5 4)

All our publications
    Blood and lymphatic diseases - miscellaneous Bone and cartilage diseases Disability Drug therapy Hematologic cancers Paediatrics Transfusions, transplantations Virus diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
aKPtKPyXhTcwBnBn